Acutely Decompensated Heart Failure in a County Emergency Department: A Double Blind Randomized Controlled Comparison of Nesiritide vs. Placebo Treatment
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 1
- 主要终点
- The primary outcome measure of 30 day readmission to the ED or readmission after an 8-hr infusion of nesiritide, in addition to standard care, compared to placebo plus standard care
研究概览
简要总结
The purpose of this study is to determine if an 8hr infusion of nesiritide in the emergency department in the Acutely decompensated heart failure patients will decrease 30 day recidivism.
详细描述
In view of the high return admission rate to our county ED for heart failure, we hypothesized that our higher risk patient population might realize a decrease in the return admission rate as a benefit from early ED administration of nesiritide. We also acknowledged that the safety of nesiritide in our patient population had not been well established. Thus, we opted to test the hypothesis that an 8-hour ED infusion of nesiritide [in addition to protocol specified standard therapy] in ADHF patients from an urban patient population consisting of predominately African Americans and Hispanics will decrease 30-day readmission rates without provoking harm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were adults greater than 18 years of age
- •A history of established heart failure
- •Dyspnea at rest or with minimal exertion and with a respiratory rate greater than 24 breaths per minute
- •Evidence of volume overload based on physical exam findings or chest radiograph, and a brain natriuretic peptide (BNP) level greater than 100 pg/ml.
排除标准
- •Systolic blood pressure of less than 90 mm Hg
- •Frank or impending cardiogenic shock
- •Cardiopulmonary arrest
- •Evidence of low cardiac output (cold clammy extremities
- •Mental status changes)
- •New onset congestive heart failure
- •Suspected acute coronary syndrome (elevated troponin, New electrocardiographic changes, or history consistent with cardiac ischemia)
- •High clinical suspicion of pulmonary embolism
- •End-stage renal disease (on dialysis or imminent)
- •Active use of nitroglycerin or inotropic infusions in the ED
- •Ventricular tachycardia
- •Allergy to nesiritide or its components
- •Patient not needing intravenously diuretic therapy in the ED
- •Normal BNP level
- •Inability to follow-up
- •Pregnancy or suspected pregnancy; or
- •Actively receiving other investigational drug.
研究组 & 干预措施
1
The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
干预措施: recombinant B-type, natriuretic peptide (Drug)
2
The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
干预措施: placebo (Drug)
结局指标
主要结局
The primary outcome measure of 30 day readmission to the ED or readmission after an 8-hr infusion of nesiritide, in addition to standard care, compared to placebo plus standard care
时间窗: 30-day
次要结局
- Secondary outcome measures included admission to the hospital after an 8-hr infusion of nesiritide, return to the ED or readmission at 7 days, 60 days, and 90 days(90-days)